Evolus (NASDAQ:EOLS) Given New $20.00 Price Target at HC Wainwright

Key Points

• HC Wainwright has **lowered its price target** for Evolus (NASDAQ:EOLS) from **$27.00 to $20.00**, while maintaining a "buy" rating, indicating a potential upside of **124.47%** from the current price.
• Other analysts have set varying price targets, with BTIG Research initiating coverage at **$21.00** and Needham & Company reaffirming a **$22.00** price target, contributing to a consensus rating of **"Moderate Buy."**
• Recent insider trading saw CFO Sandra Beaver sell **6,494 shares** of Evolus, reflecting a **3.74%** decrease in her ownership, highlighting active insider trading amid shifting stock valuations.

Evolus (NASDAQ:EOLS - Free Report) had its target price decreased by HC Wainwright from $27.00 to $20.00 in a research note published on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other equities research analysts have also recently issued reports on the stock. Needham & Company LLC reissued a "hold" rating and issued a $22.00 target price on shares of Evolus in a research report on Wednesday. BTIG Research began coverage on Evolus in a research note on Thursday, April 17th. They issued a "buy" rating and a $21.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $21.25.

Evolus Price Performance

EOLS stock traded down $0.17 during midday trading on Wednesday, hitting $5.90. 2,722,368 shares of the stock were exchanged, compared to its average volume of 1,984,819. The stock has a market cap of $381.64 million, a price-to-earnings ratio of -6.02 and a beta of 1.12. The company has a debt-to-equity ratio of 22.00, a quick ratio of 2.16 and a current ratio of 2.27. Evolus has a fifty-two week low of $5.85 and a fifty-two week high of $17.82. The stock's 50-day moving average price is $9.25 and its 200-day moving average price is $11.12.

Insider Buying and Selling

In other Evolus news, Director Albert G. White III bought 20,000 shares of the firm's stock in a transaction on Monday, June 9th. The stock was purchased at an average cost of $9.45 per share, with a total value of $189,000.00. Following the completion of the purchase, the director owned 50,378 shares in the company, valued at approximately $476,072.10. The trade was a 65.84% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider David Moatazedi sold 111,323 shares of the firm's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $10.05, for a total value of $1,118,796.15. Following the completion of the transaction, the insider owned 381,509 shares of the company's stock, valued at $3,834,165.45. The trade was a 22.59% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 153,571 shares of company stock valued at $1,537,090. 5.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Evolus

Several hedge funds and other institutional investors have recently modified their holdings of the stock. KLP Kapitalforvaltning AS bought a new position in shares of Evolus during the fourth quarter worth approximately $106,000. Geode Capital Management LLC grew its position in shares of Evolus by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 1,214,590 shares of the company's stock worth $13,412,000 after buying an additional 3,969 shares during the period. ExodusPoint Capital Management LP acquired a new stake in Evolus in the 4th quarter valued at $149,000. Wells Fargo & Company MN lifted its holdings in shares of Evolus by 41.6% in the fourth quarter. Wells Fargo & Company MN now owns 49,347 shares of the company's stock valued at $545,000 after purchasing an additional 14,506 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd boosted its stake in shares of Evolus by 60.3% in the 4th quarter. Dynamic Technology Lab Private Ltd now owns 18,886 shares of the company's stock worth $208,000 after buying an additional 7,103 shares during the last quarter. Institutional investors own 90.69% of the company's stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.